Mya has been working in regulatory, quality and clinical affairs for in vitro diagnostic products since 1990. Mya has worked with FDA and many worldwide regulatory agencies on a variety of technologies, sample types and disease states.

She has obtained clearances and approvals for single analyte assays as well as complex multiplex algorithm products.

Mya was selected for the FDA Special Commissioners Award for her work with the CDC on H1N1. Mya started Myraqa, Inc, a boutique regulatory consulting firm in 2006 and sold Myraqa to Illumina, Inc in 2014 and then served as Illumina’s VP of Regulatory, Clinical and Medical Affairs until 2017.